ADA

Diabetes Tech: A Catalyst Rich Sector with a Dazzling Future
Diabetes Tech: A Catalyst Rich Sector with a Dazzling Future
Medical Devices and Diagnostics Industry
Medtech
diabetes
ADA
Abbott Labs
DexCom
CGMs
Senseonics
Medtronic
Omnipod 5
Flag link:
Medtronic links 780G insulin pump to benefits in kids as it works to grow sales
Medtronic links 780G insulin pump to benefits in kids as it works to grow sales
Medtech Dive
Medtronic
Medtech
diabetes
pediatric
ADA
MiniMed 780G
insulin pumps
Flag link:
ADA says all diabetes patients should be screened for nonalcoholic fatty liver disease
ADA says all diabetes patients should be screened for nonalcoholic fatty liver disease
Stat
ADA
diabetes
NASH
Flag link:
ADA 2023 preview – Lilly’s oral obesity data leave room for Pfizer
ADA 2023 preview – Lilly’s oral obesity data leave room for Pfizer
EP Vantage
ADA
Eli Lilly
Pfizer
diabetes
obesity
orforglipron
danuglipron
lotiglipron
Flag link:
ADA: Bayer builds its case for potential kidney disease blockbuster Kerendia
ADA: Bayer builds its case for potential kidney disease blockbuster Kerendia
Fierce Pharma
ADA
diabetes
Bayer
chronic kidney disease
Kerendia
Flag link:
ADA 2021: After strong showing for Soliqua against premixed insulin, Sanofi exec expects 'a lot of interest' among doctors
ADA 2021: After strong showing for Soliqua against premixed insulin, Sanofi exec expects 'a lot of interest' among doctors
Fierce Pharma
ADA
diabetes
Sanofi
Soliqua
Flag link:
Study: Pfizer's Experimental Diabetes Drug Robustly Reduces Weight and Glucose
Study: Pfizer's Experimental Diabetes Drug Robustly Reduces Weight and Glucose
BioSpace
ADA
diabetes
Pfizer
PF-06882961
Flag link:
ADA: Merck, Pfizer's Steglatro rings up CV safety win but still lags heart-helping peers
ADA: Merck, Pfizer's Steglatro rings up CV safety win but still lags heart-helping peers
Fierce Pharma
ADA
diabetes
Merck
Pfizer
Steglatro
Flag link:
ADA: AstraZeneca's diabetes-fighter Farxiga cuts risk of fast decline in kidney function
ADA: AstraZeneca's diabetes-fighter Farxiga cuts risk of fast decline in kidney function
Fierce Pharma
AstraZeneca
Farxiga
chronic kidney disease
ADA
diabetes
Flag link:
Why MannKind Stock Crushed it Monday
Why MannKind Stock Crushed it Monday
Motley Fool
MannKind
ADA
diabetes
insulin
Afrezza
inhaled insulin
Flag link:
ADA: Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data show
ADA: Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data show
Fierce Pharma
ADA
diabetes
Eli Lilly
Trulicity
Novo Nordisk
Ozempic
Flag link:
ADA: Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugar
ADA: Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugar
Fierce Pharma
ADA
diabetes
Sanofi
Soliqua
type 2 diabetes
Flag link:
ADA: Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2
ADA: Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2
Fierce Pharma
ADA
diabetes
Novo Nordisk
insulin icodec
Sanofi
Lantus
insulin
Flag link:
Key data on Medtronic's 780G, Insulet's Horizon kick off ADA 2020
Key data on Medtronic's 780G, Insulet's Horizon kick off ADA 2020
Medtech Dive
ADA
diabetes
devices
Medtech
Insulet
Medtronic
780G
Horizon insulin delivery system
Flag link:
Fresh analysis spotlights cardio benefit of J&J's Invokana in diabetes patients without history of CV disease
Fresh analysis spotlights cardio benefit of J&J's Invokana in diabetes patients without history of CV disease
Endpoints
JNJ
Invokana
ADA
diabetes
cardiovascular disease
Flag link:
ADA: Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety study
ADA: Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety study
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
ADA
diabetes
Tradjenta
Flag link:
Sanofi's Soliqua Edges Out Competitors in Blood Sugar Control Trial
Sanofi's Soliqua Edges Out Competitors in Blood Sugar Control Trial
Biopharma Dive
Sanofi
diabetes
ADA
Soliqua
clinical trials
Flag link:
Provention’s Teplizumab Can Delay Onset of Type 1 Diabetes, Trial Results Show
Provention’s Teplizumab Can Delay Onset of Type 1 Diabetes, Trial Results Show
BioSpace
Povention Bio
clinical trials
type 1 diabetes
ADA
immunotherapy
Flag link:
ADA: AstraZeneca's Farxiga scores in kidney outcomes study
ADA: AstraZeneca's Farxiga scores in kidney outcomes study
Fierce Pharma
AstraZeneca
ADA
Farxiga
clinical trials
renal disease
Flag link:
Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist
Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist
Fierce Biotech
Eli Lilly
NASH
tirzepatide
clinial trials
ADA
type 2 diabetes
Flag link:

Pages